Tuesday, October 4, 2022


Biotechnology News Magazine

Dante Labs Partnering with The Renato Dulbecco Foundation

To advance personalized medicines for cancer, COVID-19 and rare diseases

Latest Posts

Sonrava Health to Include the PreTRM® Test in Its Employee Maternity Benefits Package in Collaboration with Cerebrae and Sera Prognostics

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and...

BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test

BRAINBox Solutions notes the new patent covers both diagnosis of TBI and patient monitoring post-injury, particularly for determining return to work or play.

New Initiative Brings Leading Life Sciences Companies Together To Drive Collective Impact in Awareness, Diagnosis, Care, and Health Equity for Patients with Amyloidosis

Despite notable progress in recent years, amyloidosis patients continue to experience high unmet needs and gaps in treatment and support.

GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology

Steven Boyages, CEO of GBS Inc. stated, “We believe this acquisition generates significant value for our shareholders, and I am extremely excited to be on the forefront of this transition. Bringing IFP under the GBS umbrella marks a significant advancement toward achieving our strategic goals of improving patients’ lives outside of saliva-based glucose testing and laying the pathway in becoming a leader in the development of rapid, non-invasive diagnostic solutions. We remain excited to accelerate our strategy and revenue growth through this collaboration with IFP.”

Dante Labs, a global leader in genomics and precision medicine, today announced it has partnered with The Renato Dulbecco Foundation to deliver more personalized therapies in rare diseases, oncology and COVID-19. Protelica, the groundbreaking US biotechnology company, has licensed its library of billions of pronectines nanoantibodies and a portfolio of 12 patents to The Renato Dulbecco Foundation.

As part of the drug discovery partnership, The Renato Dulbecco Foundation will leverage the Dante Platform to identify nanoantibodies and their efficacy for a wide range of applications, including for the experimental treatment of COVID-19 and all its variants resistant to traditional therapies and orphan diseases. Additional R&D activities will be outsourced to Twist Biosciences.

“Personalized medicine needs personalized data, and it is through partnerships like ours with The Renato Dulbecco Foundation that we can utilize the power of genomic information to treat diseases and ultimately deliver better health outcomes for patients,” said Andrea Riposati, CEO of Dante Labs.

“I strongly believe that this collaboration will lead to the discovery of new pronectines that must be considered a next-generation medicine and will open the avenues for the treatment of still incurable diseases,” said Prof. Giuseppe Nisticò, leader of the Renato Dulbecco Foundation and former member of European Medicine Agency (EMA) CHMP (Committee for Human Medical Products) and EMA management board.

The partnership received the enthusiastic endorsement of Dr. Roberto Crea, scientific director of The Renato Dulbecco Foundation, the famous scientist, biotechnology pioneer, and early Genentech employee.

The Renato Dulbecco Foundation was selected to receive government funds of approximately USD 30 million (ca. 27 million euros) and will have employment impact for at least 100 people, including researchers, collaborators and employees.

The institute is named after and celebrates Nobel Laureate Renato Dulbecco, the famed Italian–American molecular biologist and virologist who was awarded the 1975 Nobel Prize in Physiology and Medicine for his work on oncoviruses and in cancer. He is considered the father of human genome decodification.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine